| Module ID |
Description |
# of Compounds |
|
A06 |
All data from misc Carcin. databases |
208 |
|
A0E |
CPDB Mouse Carcinogenicity |
633 |
|
A0D |
CPDB Rat Carcinogenicity |
742 |
|
A0C |
CPDB Rodent Carcinogenicity |
430 |
|
A0L |
Mouse Two Stage Skin Carcinogenicity |
206 |
|
A01 |
N-Nitroso compounds- 5% Daily Intake in Rats |
64 |
|
A0H |
NTP Female Mouse Carcinogenicity |
286 |
|
A0F |
NTP Female Rat Carcinogenicity |
287 |
|
A0I |
NTP Male Mouse Carcinogenicity |
286 |
|
A0G |
NTP Male Rat Carcinogenicity |
314 |
|
A08 |
NTP Mouse Carcinogenicity |
319 |
|
A09 |
NTP Rat Carcinogenicity |
316 |
|
A07 |
NTP Rodent Carcinogenicity |
313 |
|
A0J |
Human carcinogenicity IARC |
628 |
|
AX1 |
Hepatocarcinogenicity MALE RAT |
474 |
|
AX2 |
hepatocarcinogenicity FEMALE RAT |
441 |
|
AX3 |
hepatocarcinogenicity MALE MOUSE |
434 |
|
AX4 |
hepatocarcinogenicity FEMALE MOUSE |
429 |
|
AF1 |
FDA Rodent Carcinogenicity Male Rat (non-proprietary) |
1245* |
|
AF2 |
FDA Rodent Carcinogenicity Female Rat (non-proprietary) |
1239* |
|
AF3 |
FDA Rodent Carcinogenicity Male Mouse (non-proprietary) |
1127* |
|
AF4 |
FDA Rodent Carcinogenicity Female Mouse (non-proprietary) |
1137* |
|
AFU |
FDA Male/Female rat and mouse (non-proprietary)(research
only) |
1445* |
|
AFV |
FDA Male/Female rat (non-proprietary) |
1298* |
|
AFW |
FDA Male/Female mouse (non-proprietary) |
1151* |
|
AG1 |
FDA Rodent Carcinogenicity Male Rat (+proprietary) |
1381* |
|
AG2 |
FDA Rodent Carcinogenicity Female Rat (+proprietary) |
1376* |
|
AG3 |
FDA Rodent Carcinogenicity Male Mouse (+proprietary) |
1252* |
|
AG4 |
FDA Rodent Carcinogenicity Female Mouse (+proprietary) |
1263* |
|
AGU |
FDA Male/Female rat and mouse (+proprietary)(research
only) |
1589* |
|
AGV |
FDA Male/Female rat (+proprietary) |
1435* |
|
AGW |
FDA Male/Female mouse (+proprietary) |
1277* |
| Module ID |
Description |
# of Compounds |
|
A0K |
Inducing Glutathione S. Transferase positive preneoplastic
lesions inrat livers |
100 |
|
A0S |
Cell Transformation - Balb/C 3T3 |
183 |
|
A0T |
TCDD+PAH Binding to Aryl Hydrocarbon Hydroxylase receptor |
148 |
|
A6C |
Inhibition of Metabolic Cooperation for cultured cells |
251 |
|
A8D |
FDA cell
transformation composite (research only) |
642* |
|
A8E |
FDA cell
transformation SHE cells (research only) |
427* |
|
A8F |
FDA cell
transformation BALB/c 3T3 cells (research only) |
317* |
|
A8G |
FDA cell
transformation C3H10T1/2 cells (research only) |
139* |